Arcutis Gets Ready to Submit an sNDA for Roflumilast cream 0.15% in Kids with AD, Ages 2 to 5
Once-daily roflumilast cream 0.05% (Zoryve, Arcutis) showed durable efficacy and favorable safety profile in the treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, according to results from the INTEGUMENT-OLE long-term open-label study. Arcutis intends to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug […]